VISEN Pharmaceuticals repurchased 8,800 ordinary shares on 20 May 2026 via on-market transactions on the Hong Kong Stock Exchange, paying an aggregate HK$0.21 million at prices ranging from HK$23.40 to HK$24.88 per share (volume-weighted average: HK$24.41).

Post-transaction, the company’s outstanding share capital (excluding treasury stock) declined marginally to 113.90 million shares from 113.91 million, representing a 0.008% reduction. Treasury shares increased from 15,400 to 24,200, while the total issued share count remained unchanged at 113.93 million.

The repurchases were executed under the mandate approved on 27 June 2025, which allows for up to 11.39 million shares to be bought back. Cumulative repurchases under this mandate now total 24,200 shares, equivalent to 0.02% of the shares outstanding on the mandate date.

A moratorium on issuing new shares or selling treasury shares is in effect until 19 June 2026, in accordance with Hong Kong listing regulations.